Korro Bio Past Earnings Performance
Past criteria checks 0/6
Korro Bio's earnings have been declining at an average annual rate of -33.6%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-33.6%
Earnings growth rate
46.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -48.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Korro Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -88 | 45 | 51 |
| 30 Jun 24 | 0 | -85 | 43 | 49 |
| 31 Mar 24 | 0 | -81 | 40 | 45 |
| 31 Dec 23 | 0 | -81 | 37 | 48 |
| 30 Sep 23 | 0 | -72 | 28 | 46 |
| 30 Jun 23 | 0 | -69 | 27 | 44 |
| 31 Mar 23 | 0 | -64 | 23 | 42 |
| 31 Dec 22 | 0 | -58 | 21 | 38 |
Quality Earnings: KRRO is currently unprofitable.
Growing Profit Margin: KRRO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KRRO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KRRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KRRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: KRRO has a negative Return on Equity (-48.88%), as it is currently unprofitable.